BioCentury
ARTICLE | Clinical News

C2N-8E12: Phase I started

July 27, 2015 7:00 AM UTC

C2N began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of IV C2N-8E12 in about 32 patients. FDA also granted Orphan Drug designation to the product for PSP...